Targeting Plasmodium falciparum transmission with primaquine: Same efficacy, improved safety with a lower dose?

Expert Review of Clinical Pharmacology

Volumn 7, Issue 6, 2014, Pages 681-686

  Chen, Ingrid T ^a   Gosling, Roly D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

8 aminoquinoline; asymptomatic malaria; drug safety; G6PD; gametocytes; hemolysis; malaria; Plasmodium falciparum; primaquine; transmission blocking

Indexed keywords

ARTEMISININ; PRIMAQUINE; ANTIMALARIAL AGENT;

AFRICAN; ASIA; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; GAMETOCYTE; HEMOLYSIS; HUMAN; INSECTICIDE RESISTANCE; MALARIA; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; REVIEW; WESTERN HEMISPHERE; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; MALARIA, FALCIPARUM; TRANSMISSION;

ANTIMALARIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PRIMAQUINE;

EID: 84911949858     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.948421     Document Type: Review

References (42)

1. WHO. World Malaria Report 2013. World Health Organization; Geneva: 2013
2. Cotter C, Sturrock HJ, Hsiang MS, et al. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet 2013;382:900-11
3. Greenwood BM, Fidock DA, Kyle DE, et al. Malaria: progress, perils, and prospects for eradication. J Clin Invest 2008;118: 1266-76
4. Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev 2011;24:377-410
5. White NJ. Primaquine to prevent transmission of falciparum malaria. Lancet 2013;13:175-81
6. Okell LC, Bousema T, Griffin JT, et al. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun 2012;3:1237
7. Baird JK. Eliminating malaria-all of them. Lancet 2010;376:1883-5
8. Recht J, Ashley E, White N. Safety of 8-aminoquinoline antimalarial medicines. World Health Organization; Geneva; 2014
9. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008;371:64-74
10. Mueller O, Mockenhaupt FP, Marks B, et al. Haemolysis risk in methylene blue treatment of G6PD-sufficient and G6PD-deficient West-African children with uncomplicated falciparum malaria: a synopsis of four RCTs. Pharmacoepidemiol Drug Saf 2013;22: 376-85
11. Shanks GD, Oloo AJ, Aleman GM, et al. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against plasmodium falciparum malaria. Clin Infect Dis 2001;33:1968-74
12. Guttmann P, Ehrlich P. Ueber die wirkung des methylen-blau bei malaria. Berlin Klin Wochenschr 1891;28:953-6
13. Avula B, Tekwani BL, Chaurasiya ND. Profiling primaquine metabolites in primary human hepatocytes using UHPLC-QTOF-MS with 13C stable isotope labeling. J Mass Spec 2013;48: 276-85
14. Medicines for Malaria Venture Project Portfolio. Available from: http://www.mmv. org/research-development/rd-portfolio [Last accessed 7 July 2014]
15. WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ 1989;67:601-11
16. Howes RE, Piel FB, Patil AP, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med 2012;9:e1001339
17. Leslie T, Bricenõ M, Mayan I, et al. The impact of phenotypic and genotypic G6PD deficiency on risk of plasmodium vivax infection: a case-control study amongst Afghan refugees in Pakistan. PLoS Med 2010;7:e1000283
18. Ruwende C, Khoo SC, Snow RW, et al. Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature 1995;376:246-9
19. Graves PM, Gelbrand H, Garner P. Primaquine for reducing Plasmodium falciparum transmission (review). Cochrane Database Syst Rev 2012;9:CD008152
20. Graves PM, Gelbrand H, Garner P. Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission (review). Cochrane Database Syst Rev 2014;6:CD008152
21. Howes RE, Battle KE, Satyagraha AW, et al. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol 2013;81:133-201
22. White NJ, Qiao LG, Qi G, Luzzatto L. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J 2012;11:418
23. Rieckmann KH, McNamara JV, Frischer H, et al. Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine/ pyrimethamine in a chloroquine-resistant strain of Plasmodium falciparum. Bull World Health Organ 1968;38:625-32
24. Updated WHO Policy Recommendation, October. 2012. Available from: http://www. who.int/malaria/pq-updated-policy-recommendation-en-102012.pdf [Last accessed 7 July 2014]
25. Pharmacokinetic study of primaquine and dihydroartemisinin-piperaquine in healthy subjects. Available from: http://clinicaltrials. gov/show/NCT01525511
26. Primaquine's gametocytocidal efficacy in malaria asymptomatic carriers (PRINOGAM). Available from: http:// clinicaltrials.gov/show/NCT01838902
27. Low dose primaquine for clearance of gametocytes (LOPRIM). Available from: http://clinicaltrials.gov/show/NCT01935882
28. The optimal timing of primaquine to prevent malaria transmission after artemisinin-combination therapy. Available from: http://clinicaltrials.gov/show/ NCT01906788
29. Antimalarial drug resistance with assessment of transmission blocking activity. Available from: http://clinicaltrials.gov/show/ NCT01849640
30. Evaluation of the gametocytocidal efficacy and safety of primaquine in uncomplicated falciparum malaria in uganda. Available from: http://clinicaltrials.gov/show/ NCT01365598
31. Eziefula AC, Bousema T, Yeung S, et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. Lancet Infect Dis 2014;14:130-9
32. Bennett JW, Pybus BS, Yadava A, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 2013;269:1381-2
33. Pybus BS, Marcsisin SR, Jin X, et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J 2013;12:212
34. Shekalaghe SA, ter Braak R, Daou M, et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) Individuals. Antimicrob Agents Chemother 2010;54:1762-8
35. Shekalaghe S, Drakeley C, Gosling R, et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS One 2007;10:e1023
36. Cui L, Yan G, Sattabongkot J, et al. Challenges and prospects for malaria elimination in the Greater Mekong Subregion. Acta Trop 2012;121:240-5
37. Fernando D, Rodrigo C, Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar J 2011;10:351
38. Eziefula AC, Gosling RG, Hwang J, et al. Rationale for short course primaquine in Africa to interrupt malaria transmission. Malar J 2012;11:360
39. Howes RE, Dewi M, Piel FB, et al. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malaria J 2013;12:418
40. Pharmacokinetic study of primaquine and pyronaridine-artesunate in healthy subjects. Available from: http://clinicaltrials.gov/show/ NCT01552330
41. Pharmacokinetic study of primaquine and dihydroartemisinin-piperaquine in healthy subjects. Available from: http://clinicaltrials. gov/show/NCT01525511
42. Johnston GL, Gething PW, Hay SI, et al. Modeling within-host effects of drugs on Plasmodium falciparum transmission and prospects for malaria elimination. PLoS Comput 2014;10:e1003434